image description

Tag: Lupus Clinical Investigators Network

Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network

NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.  Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […] Read More

Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population

ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8, 2022 — The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus […] Read More

NIH Awards $500,000 to Advance to Advance Diversity in Lupus Trials

August 31, 2022 We are excited to share good news – our Lupus Clinical Investigators Network, LuCIN, managed by LRA’s affiliate Lupus Therapeutics, will be working on a new research project to increase diverse representation of patients in lupus trials to be funded with a $500,000 National Institutes of Health Innovation Award from the Food […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

LRA is Unraveling Lupus Heterogeneity to Turn Complexity to Cure

July 22, 2021 Why is lupus so tough to treat? Why is it so difficult to test possible new treatments in a clinical trial? Why are so many people needed for a clinical trial to prove effectiveness? And how does LRA intend to Turn Lupus Complexity to Cure? The answers lie at the core of […] Read More

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates